Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FGBS0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, awarded on January 30, 2026, with an ultimate completion date of February 23, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal military medical supply chain, holding a single-award IDC under the PPV-G GEN V program with a ceiling value of $499,999,999 and completion date of December 31, 2036. The company's product portfolio encompasses an extensive range of branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with demonstrated performance across multiple therapeutic categories including oncology treatments, immunosuppressants, and emergency medications. As one of multiple regional prime vendor contractors under the broader PPV-G GEN V strategy, DMS Pharmaceutical Group leverages its small business status to serve as a key pharmaceutical supplier supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FGBS0?
SPE2DR26FGBS0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FGBS0 worth?
The government has obligated $16,584 on SPE2DR26FGBS0.
Is contract SPE2DR26FGBS0 an order under another contract?
Yes. SPE2DR26FGBS0 is a delivery order under SPE2DR25D9315, an indefinite delivery contract.
Was contract SPE2DR26FGBS0 competed?
The extent of competition for SPE2DR26FGBS0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award